GoPath Diagnostics

11/27/2025

Happy Thanksgiving from all of us at GoPath Diagnostics!

We’re grateful for the trust and collaboration of our partners, clinicians, and patients who make our work meaningful every day. Wishing you and your loved ones a wonderful holiday filled with gratitude and good health.

11/24/2025

MODY is often overlooked, yet it’s one of the most important monogenic diabetes conditions clinicians encounter. Identifying the underlying gene mutation can directly influence treatment, prognosis, and family risk assessment. Early recognition = better outcomes.

11/18/2025

Diabetes is a complex condition affecting millions across all ages and backgrounds, including rare forms like MODY that require specialized diagnosis and care. Early detection and awareness are vital, as many remain undiagnosed or face challenges managing their health. Understanding diabetes means recognizing its impact—from children to seniors and diverse communities—and the importance of education, support, and personalized treatment.

11/13/2025

We’re live at AMP 2025 in Boston! Stop by booth 1110 to learn more about our OncoTarget Series and how our comprehensive genomic profiling supports precision oncology. We are excited to connect with so many experts driving advancements in molecular diagnostics!

11/11/2025

Meet Mya—a college sophomore who was diagnosed with a rare form of diabetes (HNF1A MODY) at just age ten, and has since turned challenges into strength. As a middle schooler, Mya often felt left out, but early diagnosis gave her the knowledge and skills to advocate for herself and educate others about MODY. Today, she actively raises awareness, participates in research, and encourages other young people not to let diabetes define them. Discover how Mya is shaping her future—and inspiring her community—by sharing her journey and empowering others to do the same.

https://www.uchicagomedicine.org/forefront/pediatrics-articles/hnf1a-mody-diabetes-patient-story

Mya Abuzir is now a college student living with HNF1A MODY, a rare form of diabetes caused by a mutation in a single gene.

11/10/2025

This Diabetes Awareness Month, understanding your genetic risk for diabetes has never been easier. The DiabetesNow panel tests 16 genes linked to MODY, syndromic, neonatal, and mitochondrial forms of monogenic diabetes, plus polygenic risk scores for type 1 and type 2, and GenProb-T1D to estimate the likelihood of type 1 diabetes based on genetic risk.

Built on a validated database and powered by the Global Diversity Array, DiabetesNow delivers accurate insights that support clearer diagnosis and risk assessment for people with atypical diabetes or a family history. Learn more about how genetics can guide better diabetes care.

https://geneticsnow.com/diabetesnow

11/07/2025

We’re live at the 2025 LUGPA Annual Meeting! Visit booth 410 and learn how our genomic and genetic testing solutions help urologists deliver precise, data-driven care.

11/04/2025

What if the diagnosis you’ve lived with for years wasn’t the right one?

For the Acevedo De Arias family, the answer came through our DiabetesNow™ genetic panel. The results revealed the true cause of their diabetes, a rare inherited form known as MODY (Maturity Onset Diabetes of the Young), and freed them from years of unnecessary insulin injections.

Their story highlights the power of precise diagnosis and the impact of our work in advancing personalized diabetes care.

Read more: https://www.endeavorhealth.org/articles/personalized-medicine-diabetes-story

Pictured above: The Acevedo De Arias family with Liana Billings, MD, at Endeavor Health.

10/30/2025

As Breast Cancer Awareness Month concludes, we remain committed to supporting clinicians and patients with comprehensive hereditary cancer testing. Awareness saves lives—knowledge changes care.

10/29/2025

From the Freedom Trail to the future of molecular testing—Boston, we’re coming your way!

Join us at booth 1110 during the AMP 2025 Annual Meeting & Expo to explore our OncoTarget Series and see how precision genomic profiling is transforming advanced cancer care.

The countdown to AMP 2025 is on—we can’t wait to connect with you in Boston!

10/27/2025

Danielle’s story is a reminder of how genetic testing can change — and even save — lives.

After losing her grandfather and aunt to breast cancer, and with her twin sister’s diagnosis at age 32, Danielle pursued genetic testing and learned she carried a BRCA mutation. The results revealed early-stage breast cancer, allowing her to begin treatment before the disease could progress.

She now encourages others with a family history of breast cancer to talk to their doctors about genetic testing—it may be the most important decision they make.

📖 Read the full story from the National Breast Cancer Foundation: https://www.nationalbreastcancer.org/blog/the-power-of-genetic-testing-danielles-familys-story/

Genetic testing revealed a BRCA gene mutation for Danielle and her twin sister. Danielle's decision to be proactive may have saved her life.

10/24/2025

Breast cancer remains a leading health concern for women in the U.S. One in eight women will face a diagnosis in their lifetime, and rates continue to rise in certain age groups. While earlier detection and improved treatments have increased survival, thousands still lose their lives each year. These figures highlight the ongoing need for awareness, regular screening, and timely care. This Breast Cancer Awareness Month, we’re sharing the numbers that matter.